StockData
Ligand Pharmaceuticals Inc logo

Ligand Pharmaceuticals Inc (LGND) company profile

LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)

Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –

About Ligand Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets, royalty assets, and related technologies. Its business model centers on acquiring, creating, and managing financial and intangible royalty rights across various drug development programs and partnered commercial therapies, alongside selling proprietary materials such as Captisol. The company enters into development and licensing agreements, service contracts, and collaborative partnerships with global biopharmaceutical firms and research partners to advance clinical-stage candidates and marketed products.

The company operates globally, with business partnerships and financial royalty exposure spanning the United States, Great Britain, Austria, and India. Ligand Pharmaceuticals maintains corporate office facilities in the United States, which serve as its primary operating and administrative headquarters for managing its extensive portfolio of biopharmaceutical partnerships, intellectual property assets, and licensing programs.

Summary of the business section of Ligand Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Ligand Pharmaceuticals Inc
Founded
1987
Headquarters
San Diego, CA
Address
3911 Sorrento Valley Blvd, Suite 110 92121
Phone
(858) 550-7500
Website
ligand.com
Employees
47, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst& YoungLLP, San Diego, California

Stock & identifiers

Ticker
LGND
Other tickers
LGNDZ, LGNXZ, LGNYZ, LGNZZ
Exchange
Nasdaq
IPO date
Nov 18, 1992
Shares outstanding
20M, Oct 27, 2026
Public float
$1.60B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-6 reverse, Nov 19, 2010
SEC CIK
886163
CUSIP
53220K504
ISIN
US53220K5048
FIGI
BBG000BKF014
Share class FIGI
BBG001S8CH99
LEI
5493008K7TB0IKP37H79
EIN
77-0160744

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Todd C. DavisChief Executive Officer, Director199,513
Andrew ReardonCLO & Secretary31,854
Octavio EspinozaChief Financial Officer48,818
Martine ZimmermannDirector1,782
John W. KozarichDirector42,122
Jason AryehDirector113,476
Jason HaasDirector3,981
Stephen L. SabbaDirector33,629
John L. LamattinaDirector31,071
Nancy Ryan GrayDirector8,930

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$11.47M$43.77M$4.07M$279$125
FY2024
John L.Higgins
$0$0$6.58M$158$93
FY2024
Todd C.Davis
$12.91M$21.71M$6.58M$158$93
FY2023
John L.Higgins
$0$0$2.79M$105$94
FY2023
Todd C.Davis
$6.22M$5.06M$2.79M$105$94
FY2022$5.20M$4.98M$3.85M$99$90

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Todd C. Davis
Chief Executive Officer
$724.50K$5.52M$4.44M$764.40K$21.58K$11.47M-11%
Tavo Espinoza
Chief Financial Officer
$522.83K$1.93M$1.55M$357.75K$14.94K$4.38M+33%
Andrew Reardon
Chief Legal Officer and Secretary
$476.68K$1.66M$1.33M$268.80K$13.29K$3.75M+15%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we have 47 full-time employees, of whom seven are involved directly in scientific research and development activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 14, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 17, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 18, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 4, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 1, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 31, 2020Tender offerThird-party tender offer for the company's shares
Mar 6, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 10, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 9, 2016Late filingNotification of late filing
Aug 26, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 8, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 9, 2012Late filingNotification of late filing
Apr 12, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 11, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 26, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 28, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 24, 2009Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 25, 2009MergerRegistration of securities for a merger or exchange offer (S-4)
Sep 30, 2009MergerRegistration of securities for a merger or exchange offer (S-4)
Dec 24, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 20, 2008MergerRegistration of securities for a merger or exchange offer (S-4)
Apr 7, 2008Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 28, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 24, 2007Merger voteDefinitive merger proxy statement
Nov 15, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 9, 2006Late filingNotification of late filing
Oct 31, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 17, 2006ListingRegistration of securities on an exchange (Form 8-A)
May 10, 2006Late filingNotification of late filing
Mar 16, 2006Late filingNotification of late filing

See a number that looks wrong?